UPDATE 1-Durect's pain drug shows mixed results in EU trial

* Meets one of two main goals

* Says no safety issues

June 16 (Reuters) - Durect Corp (DRRX.O) said its experimental pain drug, Posidur, met one of the two main goals of a mid-stage trial in Europe.

Durect is co-developing Posidur with Swiss drug firm Nycomed [NYCMD.UL] to treat post-operative pain.

Posidur met the first primary endpoint of showing non-inferiority to a combination of another pain drug, Saber, and a dummy drug.

On the second primary efficacy endpoint, no statistically significant difference was shown in opioid use between the Posidur and Saber-placebo groups, the company said.

Durect said there were no indications of systemic safety issues.

Posidur, a long-acting version of the anesthetic bupivacaine, is currently in late-stage studies in the United States to treat post-operative pain.

"We are currently enrolling in BESST, our U.S. pivotal Phase III study and Nycomed continues to enroll in a Phase IIb study in Europe in shoulder surgery," Durect said.

Shares of the company closed at $2.82 Wednesday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Vinu Pilakkott)